Abstract |
In the 2001 U.S. bioterror attacks, 33,000 individuals required postexposure prophylaxis, 18 subjects contracted anthrax (11 inhalation, 7 cutaneous), and despite optimal medical therapy, 5 deaths resulted. Rapid protection against anthrax is required in a bioterrorism scenario; this study describes an in vivo gene transfer-based therapy that uses a human adenovirus (Ad)-based vector (AdalphaPAscAb) encoding a single-chain antibody directed against protective antigen (PA), a critical component of Bacillus anthracis lethal toxin. Following AdalphaPAscAb administration to mice, anti-PA single-chain antibody and anti-PA neutralizing activity were detected in serum over a 2-week period. Substantial survival advantage from anthrax lethal toxin was conferred by AdalphaPAscAb following administration from 1 to 14 days prior to toxin challenge, compared to no survival associated with an Ad vector expressing a control single-chain antibody. Passive immunotherapy with an Ad-based vector may be a rapid, convenient approach for protecting a susceptible population against anthrax, including use as an adjunct to antibiotic therapy.
|
Authors | Kazuhiko Kasuya, Julie L Boyer, Yadi Tan, D Olivier Alipui, Neil R Hackett, Ronald G Crystal |
Journal | Molecular therapy : the journal of the American Society of Gene Therapy
(Mol Ther)
Vol. 11
Issue 2
Pg. 237-44
(Feb 2005)
ISSN: 1525-0016 [Print] United States |
PMID | 15668135
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Anthrax Vaccines
- Antibodies, Bacterial
- Antigens, Bacterial
- Bacterial Toxins
- anthrax toxin
|
Topics |
- Adenoviridae
(genetics)
- Animals
- Anthrax Vaccines
(genetics, immunology)
- Antibodies, Bacterial
(administration & dosage, genetics, immunology)
- Antigens, Bacterial
(immunology)
- Bacterial Toxins
(antagonists & inhibitors, immunology)
- Gene Expression
(genetics)
- Immunization, Passive
(methods)
- Mice
- Survival Rate
|